Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Emergent BioSolutions Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Emergent BioSolutions Inc. (EBS) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Emergent BioSolutions Inc. (“Emergent” or “the Company”) (NYSE: EBS). Investors who purchased Emergent securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Emergent has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On August 5, 2026, Emergent reported results for the quarter ended June 30, 2026. Among other items, Emergent announced, among other things, a $191.3 million non-cash impairment charge on the NARCAN asset group, driving a GAAP net loss of $180.2 million. The Company also cut full-year revenue guidance by approximately 10.8% at the midpoint. Management attributed its results to “increased competitive intensity with implications for our near to medium term outlook and the book value of our NARCAN asset group.” Following this news, Emergent’s stock price dropped $2.23 per share, or 29.58%, to close at $5.31 on August 6, 2026.
What Should Emergent BioSolutions Inc. (EBS) Investors Do?
If you are aware of any facts relating to this investigation or purchased Emergent securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Did Emergent BioSolutions Inc. (EBS) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”